SK Bioscience Co Ltd
KRX:302440
SK Bioscience Co Ltd
Total Assets
SK Bioscience Co Ltd
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Total Assets
₩2.8T
|
CAGR 3-Years
10%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Total Assets
₩21.1T
|
CAGR 3-Years
55%
|
CAGR 5-Years
40%
|
CAGR 10-Years
25%
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Total Assets
₩939.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Total Assets
₩855.7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Total Assets
₩409B
|
CAGR 3-Years
16%
|
CAGR 5-Years
37%
|
CAGR 10-Years
27%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Total Assets
₩232B
|
CAGR 3-Years
52%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
SK Bioscience Co Ltd
Glance View
SK Bioscience Co Ltd., a remarkable enterprise carved out of the South Korean corporate landscape, operates at the dynamic intersection of biotechnology and pharmaceuticals. A part of the larger SK Group, one of Korea's leading conglomerates, the company was officially established in 2018 from SK Chemicals' life sciences division. Its primary focus is on developing and manufacturing vaccines, serving both public health needs locally and globally. The company has swiftly gained prominence for its role in the COVID-19 pandemic, particularly with the production of vaccines in collaboration with significant players such as AstraZeneca and Novavax. This strategic engagement loop has positioned SK Bioscience not only as a critical player in health crises management but also as a pivotal contributor to global health security. At the heart of SK Bioscience's business model is its ability to leverage cutting-edge research and robust manufacturing capabilities. The firm generates revenue through various channels, including product sales of its vaccines and other pharmaceuticals, contract manufacturing services, and partnerships with global entities, allowing it a diversified income stream. Its adeptness in innovation, underpinned by a strong R&D framework, ensures a steady development pipeline, supporting long-term growth ambitions. Through these strategic activities, SK Bioscience aligns itself with the SK Group’s broader commitment to social value and environmental, social, and governance (ESG) principles, fortifying its reputation as a company that not only seeks financial success but also endeavors to wield a positive global impact.
See Also
What is SK Bioscience Co Ltd's Total Assets?
Total Assets
2.8T
KRW
Based on the financial report for Dec 31, 2024, SK Bioscience Co Ltd's Total Assets amounts to 2.8T KRW.
What is SK Bioscience Co Ltd's Total Assets growth rate?
Total Assets CAGR 5Y
48%
Over the last year, the Total Assets growth was 54%. The average annual Total Assets growth rates for SK Bioscience Co Ltd have been 10% over the past three years , 48% over the past five years .
You don't have any saved screeners yet